“The approval of FORZINITY, the first treatment option for Barth syndrome and the first approved mitochondria-targeted …
FDA denies approval for dichloroacetate (DCA), a treatment for Pyruvate Dehydrogenase Complex Deficiency (PDCD).
Earlier today, Saol Therapeutics shared the U.S. Food and Drug Administration (FDA) has issued a Complete Response …
Expert Series: The Road Ahead: Navigating the FDA Update on Elamipretide for Barth syndrome
Join MitoAction CEO, Kira Mann, Barth Syndrome Foundation CEO, Emily Milligan, and Stealth BioTherapeutics CEO, Reenie …
MitoAction Advocates for Barth Syndrome Community in FDA Listening Session
FOR IMMEDIATE RELEASE
[Boston, MA, April 1, 2024] - MitoAction, a leading nonprofit organization dedicated to …
